Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Oregon › Portland
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Portland, OR keessatti
Qorannoo 9 Kansaar Onnee Triple-Negative f Portland fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Oregon Health & Science University (OHSU), Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Portland
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center ( Site 0116), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0126), Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Namoota walitti qabaa jiraSadarkaa 2
- Providence Portland Cancer Institute - Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Namoota walitti qabaa jiraSadarkaa 3
- Oregon Health & Science University, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Compass Oncology - Rose Quarter, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Oregon Health & Science Institute (OHSU), Portland
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Los Angeles, CAQorannoo 27
- Boston, MAQorannoo 26
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Chicago, ILQorannoo 16
- Columbus, OHQorannoo 16
Qorannoo biroo Portland keessatti
- Kansara Qara'a Non-Small CellQorannoo 46
- Saree (Gosoota Hunda)Qorannoo 34
- Saree OljooQorannoo 33
- Kansarii ProstateQorannoo 33
- Kansara MetastatikiiQorannoo 29
- Kansarii ColorectalQorannoo 28
- Kansarii OvariiQorannoo 27
- Dhibee QaraQorannoo 26
- Leukemia Myeloidii HamaaQorannoo 25
- Kansa EndometiriyaaliiQorannoo 24
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 19
- Kansarii PancreasQorannoo 19
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.